A phase Ia trial of SEL-212 for treatment of refractory and tophaceous gout and tumor lysis syndrome

Trial Profile

A phase Ia trial of SEL-212 for treatment of refractory and tophaceous gout and tumor lysis syndrome

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs SEL 212 (Primary)
  • Indications Gout; Tumour lysis syndrome
  • Focus Adverse reactions; Proof of concept
  • Sponsors Selecta Biosciences
  • Most Recent Events

    • 07 Dec 2016 Results published in the Selecta Biosciences Media Release
    • 07 Dec 2016 According to a Selecta Biosciences media release, all patient visits has been completed in this and other Phase I trial (266205).
    • 26 Oct 2016 Results from this and another phase I trial will be presented at the 11th Annual Immunization and Vaccine Summit (IMVACS) 2016, according to a Selecta Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top